Loading...
Loading...
In a report published on Tuesday, Morgan Stanley analyst Ricky R Goldwasser downgraded Quest Diagnostics Inc.
DGX to Underweight and initiated a price target of $58.00.
In the report, Morgan Stanley noted, "Last night, CMS published a proposal to lower reimbursement rates for lab tests covered under the Physician Fee Schedule (PFS) by 26%. The proposed changes to reimbursement, which follows a ~35% cut in 2013, is more negative then our earlier expectations/prior model forecasts."
Quest Diagnostics closed on Monday at $61.25.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in